

## Conference Schedule / Thursday May 3, 2012

- 7:30-8:30**      **Breakfast and Registration** (2nd Level, Grand Banking Hall)
- 8:30-8:45**      **Welcome and Introduction**  
Michael Sherar, President & CEO, Cancer Care Ontario  
David Jaffray, Acting Chair, UT DRO
- 8:45-9:30**      **Keynote Address**  
*Growth and Acceptance of SBRT for Treatment of Primary and Metastatic Cancers*  
Paul Okunieff  
Objectives: After this session, the attendees will be able to  
• discuss staging metastases in defining new clinical trials.  
• define evidence of oligometastases.  
• discuss historical successes of local treatments for control of metastases.
- 9:30-9:45**      **Question and Answer Period**
- 9:45-10:15**      **Break**
- 10:15-11:45**      **Session 1 – Lung Cancer**  
Moderator: Patrick Cheung  
Objectives: After this session, the attendees will be able to  
• evaluate clinical outcomes related to and discuss the technical aspects of delivering SBRT in lung cancers.  
• discuss the need for quality assurance and apply standards of care when adopting new treatment techniques.
- 10:15-10:35      *Should SBRT be the Standard of Care for Medically Inoperative Early Stage Lung Cancer?*  
David Palma
- 10:35-10:45      Question and Answer Period
- 10:45-11:05      *Technologic Advances in Lung SBRT*  
Jean-Pierre Bissonnette
- 11:05-11:15      Question and Answer Period
- 11:15-11:35      *Should there be Provincial Guidelines Regarding the Use of SBRT?*  
Patrick Cheung
- 11:35-11:45      Question and Answer Period
- 11:45-1:15**      **Lunch**

## Conference Schedule / Thursday May 3, 2012

### 1:15-2:45      **Session 2 – Prostate Cancer**

Moderator: Michael Sharpe

Objectives: After this session, the attendees will be able to

- compare and contrast clinical outcomes related to the use of SBRT and HDR Brachytherapy in prostate cancer.
- discuss the technical aspects of delivering HDR Brachytherapy for prostate cancer.

1:15-1:35      *HDR or LDR Brachytherapy for Prostate Cancer?*  
Gerard Morton

1:35-1:45      Question and Answer Period

1:45-2:05      *SBRT: Is this the Future of Radiotherapy for Prostate Cancer?*  
Andrew Loblaw

2:05-2:15      Question and Answer Period

2:15-2:35      *Physics Issues in HDR Prostate Brachytherapy*  
Ananth Ravi

2:35-2:45      Question and Answer Period

### 2:45-3:15      **Break**

### 3:15-4:45      **Session 3 – Liver and Spine**

Moderator: Nicole Harnett

Objectives: After this session, the attendees will be able to

- evaluate clinical outcomes related to the use of SBRT in the treatment of paraspinal and liver disease.
- articulate the benefits of significant hypofractionation in these patients.
- discuss the technical challenges of delivering SBRT to these sites.

3:15-3:35      *SBRT for Spinal Metastases: How, When and Why?*  
Arjun Sahgal

3:35-3:45      Question and Answer Period

3:45-4:05      *Tumour Motion Management for Liver SBRT*  
Michael Velec

4:05-4:15      Question and Answer Period

4:15-4:35      *The Emerging Role of Stereotactic Body Radiotherapy  
in the Management of Colorectal Liver Metastases*  
William Chu

4:35-4:45      Question and Answer Period

### 4:45-6:00      **Poster Viewing and Reception (3rd Level, King Gallery)**

## Conference Schedule / Friday May 4, 2012

**7:30-8:30**      **Breakfast and Registration**

**8:30-8:45**      **Welcome and Introduction**

Patrick Cheung, Co-Chair, Organizing Committee, UT DRO

**8:45-9:30**      **Keynote Address**

*MR Brachytherapy for Cervical Cancer*

Kari Tanderup

Objectives: In this session, the attendees will be able to

- explain the principles of image-guided brachytherapy in cervix cancer.
- discuss upcoming data from clinical trials on image guided brachytherapy.

**9:30-9:45**      **Question and Answer Period**

**9:45-10:15**      **Break**

**10:15-11:45**      **Session 4 – Gynecologic Cancer**

Moderators: Ida Ackerman, Michael Milosevic

Objectives: After this session, the attendees will be able to

- evaluate clinical outcomes related to Brachytherapy for gynecological cancers.
- describe the uncertainties and controversies inherent in delivering Brachytherapy for cervical cancer.
- discuss various approaches to quality assurance and developing standards of care when adopting new treatment techniques.

10:15-10:35      *Guidelines and Standards for Cervical Cancer Brachytherapy*

Anthony Fyles

10:35-10:45      Question and Answer Period

10:45-11:05      *Interstitial Brachytherapy for Cervical Cancer*

David D'Souza

11:05-11:15      Question and Answer Period

11:15-11:35      Panel: *Cases and Controversies in Image-Guided Brachytherapy for Cervical Cancer*

Panelists: Kari Tanderup, Anthony Fyles, David D'Souza

11:35-11:45      Question and Answer Period

**11:45-1:15**      **Lunch**

## Conference Schedule / Friday May 4, 2012

### 1:15-2:45      **Session 5 – Biologic Insights**

Moderator: Lori Holden

Objectives: After this session, the attendees will be able to

- identify radiobiological mechanisms at work when significant hypofractionation is used.
- describe methods for exploiting biological and molecular characteristics to improve the therapeutic ratio in radiation therapy.

1:15-1:35      *The Biology of Hypofractionated Radiotherapy*  
Bradly Wouters

1:35-1:45      Question and Answer Period

1:45-2:05      *Multiparametric MR-Imaging of Tumour Biology to Guide Prostate Cancer Radiotherapy*  
Cynthia Ménard

2:05-2:15      Question and Answer Period

2:15-2:35      *Personalized Treatment of Brain Tumours: Integrating Radiotherapy and Molecular Therapeutics*  
Caroline Chung

2:35-2:45      Question and Answer Period

### 2:45-3:15      **Break**

### 3:15-4:15      **Session 6 – Thoughts from the Trenches**

Moderator: Miller MacPherson

Objectives: After this session, the attendees will be able to

- appreciate the realities of new program development and the challenges that must be addressed when implementing new programs/approaches.

3:15-3:30      *Timelines and Efficiency of MR-guided Brachytherapy for Cervical Cancer*  
Kitty Chan

3:30-3:35      Question and Answer Period

3:35-3:50      *Lung SBRT in Mississauga: Tips for Starting a New Program*  
Hany Soliman

3:50-3:55      Question and Answer Period

3:55-4:10      *CyberKnife Radiosurgery: A Different Approach to IGRT*  
Martin Shim

4:10-4:15      Question and Answer Period

## Conference Schedule / Friday May 4, 2012

**4:15-5:00**

### **Debate**

*Be it Resolved that HDR Brachytherapy Should be the Standard of Care in Ontario for Men with Intermediate Risk Prostate Cancer.*

For: Charles Catton

Opposed: Gerard Morton

Objectives: After this session, the attendees will be able to

- evaluate clinical outcomes related to the use of SBRT and HDR Brachytherapy for prostate cancers.
- emphasize the need for quality assurance and apply standards of care when adopting new treatment techniques.

**5:00**

### **Wrap Up**

Patrick Cheung, Co-Chair, Organizing Committee, UT DRO